UK's Oxford Biomedica tumbles after annual revenue forecast cut

Oxford Biomedica shares fell more than 24% after the company cut its 2026 revenue forecast, citing operational delays at a U.S. site and deferred client orders. The guidance reduction implies weaker demand visibility into 2026 and creates near-term earnings risk tied to execution and order timing.

Analysis

Oxford Biomedica shares fell more than 24% after the company cut its 2026 revenue forecast, citing operational delays at a U.S. site and deferred client orders. The guidance reduction implies weaker demand visibility into 2026 and creates near-term earnings risk tied to execution and order timing.